Cargando…
Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase
Liver pyruvate kinase (PKL) has recently emerged as a new target for non-alcoholic fatty liver disease (NAFLD), and inhibitors of this enzyme could represent a new therapeutic option. However, this breakthrough is complicated by selectivity issues since pyruvate kinase exists in four different isofo...
Autores principales: | Battisti, Umberto Maria, Gao, Chunixa, Akladios, Fady, Kim, Woonghee, Yang, Hong, Bayram, Cemil, Bolat, Ismail, Kiliclioglu, Metin, Yuksel, Nursena, Tozlu, Ozlem Ozdemir, Zhang, Cheng, Sebhaoui, Jihad, Iqbal, Shazia, Shoaie, Saeed, Hacimuftuoglu, Ahmet, Yildirim, Serkan, Turkez, Hasan, Uhlen, Mathias, Boren, Jan, Mardinoglu, Adil, Grøtli, Morten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919951/ https://www.ncbi.nlm.nih.gov/pubmed/36771285 http://dx.doi.org/10.3390/nu15030577 |
Ejemplares similares
-
Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning
por: Zhang, Cheng, et al.
Publicado: (2022) -
Exploration of Novel Urolithin C Derivatives as Non-Competitive Inhibitors of Liver Pyruvate Kinase
por: Battisti, Umberto Maria, et al.
Publicado: (2023) -
Serendipitous Identification of a Covalent Activator of Liver Pyruvate Kinase
por: Battisti, Umberto Maria, et al.
Publicado: (2022) -
Assessment of the neuroprotective potential of d-cycloserine and l-serine in aluminum chloride-induced experimental models of Alzheimer’s disease: In vivo and in vitro studies
por: Tozlu, Özlem Özdemir, et al.
Publicado: (2022) -
Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer’s disease patients
por: Bayraktar, Abdulahad, et al.
Publicado: (2023)